Fast Five Quiz: Semaglutide

Richard H. Sinert, DO


October 25, 2023

As one of 10 of the available glucagon-like peptide 1 receptor agonists (GLP-1 RAs), semaglutide is branded as Ozempic, Rybelsus, and Wegovy. Semaglutide was first developed in 2012 for use in the management of type 2 diabetes, but starting in 2018, it began to be used worldwide. Since that time, research into semaglutide and other GLP-1 RAs has exploded, with numerous new applications being explored. High patient demand for semaglutide coupled with high prices have made treatment less accessible for many patients, even as potential therapeutic uses increase. A recent survey suggests that many clinicians are likely to encounter patients asking about GLP-1 RAs despite their scarcity and cost.

Test your knowledge about semaglutide and other GLP-1 RAs, including indications, contraindications, and adverse effects, with a short quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.